Agenda
Agenda Sessions
- The session on early-stage upper GI cancers will cover adjuvant and neoadjuvant strategies, non-operative management, and treatment of oligometastatic disease through a multidisciplinary lens.
- The late-stage upper GI session will emphasize biomarker-driven therapies—including HER2, PD-L1, CLDN18.2, and FGFR2—alongside second-line options and the integration of clinical next-generation sequencing (NGS).
- Early-stage colorectal cancer will be addressed through surgical and radiation approaches, as well as emerging immunotherapy strategies.
- The late-stage colorectal session will focus on targeted therapies for BRAF, HER2, and KRAS mutations, novel chemotherapy regimens, and liver-directed and locoregional therapies.
- A dedicated hepatobiliary session will examine systemic and multidisciplinary approaches to hepatocellular carcinoma (HCC) and biliary tract cancers (BTC).
- The “Tools for Tomorrow’s Oncologist” session will spotlight ctDNA-based minimal residual disease (MRD) testing, artificial intelligence (AI), EMR-based decision support, precision medicine, and the expanding role of advanced practice providers.
- Rare tumor types will be explored through updates on small bowel malignancies, gastrointestinal stromal tumors (GIST), neuroendocrine tumors (NETs), and radiopharmaceutical therapies, including five new agents in development.
- A session on genetic insights will focus on cancer prevention and early detection, including germline testing and surveillance strategies.
- The pancreatic cancer session will address targeted therapies such as PARP inhibitors for BRCA mutations, perioperative regimens, and local treatments like stereotactic body radiotherapy (SBRT) and tumor treating fields (TTF).
- The “GI Evolving Landscape” session will explore pan-tumor approvals (e.g., MSI-H, NTRK fusions), antibody–drug conjugates (ADCs), and emerging clinical trials.
TXGI’26 will deliver a comprehensive, forward-looking program that equips oncology professionals with actionable insights. By bridging academic innovation with community practice, the conference will reinforce the value of multidisciplinary care in improving outcomes for patients with GI malignancies. Receive up to 11.5 CE credits.
Welcome day
Thursday, November 5, 2026
Poster Session & Welcome Reception
Day one
Friday, November 6, 2026
Upper GI Cancers: Early Stage Esophageal, GEJ, and Gastric
Upper GI Cancers: Late Stage
Colorectal Cancer, Part I: Early Stage
Colorectal Cancer, Part II: Late Stage
Liver & Biliary Cancers
Day two
Saturday, November 7, 2026
Tools for Tomorrow’s Oncologist
Rare Tumor Types in GI Oncology
Genetic Insights in GI Oncology
Pancreatic Cancer
Evolving Landscape in GI Oncology
Welcome day
Thursday, November 5, 2026
Poster Session & Welcome Reception
6:00 PM - 8:00 PM
ACL Live – Mezzanine Level, 2nd floor
Day one
Friday, November 6, 2026
Faculty & Fellows Breakfast
7:30 AM - 8:20 AM
W Austin Hotel, Great Room
Sponsored by: Amgen
Industry attendance is limited to breakfast symposium sponsors only
Welcome & Opening Remarks
8:30 AM - 8:50 AM
ACL Live, General Session
Chairs:
Yelena Janjigian, MD (Memorial Sloan Kettering Cancer Center)
Scott Paulson, MD
(Texas Oncology)
Upper GI Cancers: Early Stage Esophageal, GEJ, and Gastric
Session Chair: Yelena Janjigian, MD (Memorial Sloan Kettering Cancer Center)
ACL Live, General Session
8:50 AM
Adjuvant
Ronan Kelly, MD (Baylor Scott and White)
9:00 AM
Neoadjuvant
Samuel Cytryn, MD (Memorial Sloan Kettering Cancer Center)
9:10 AM
Unresectable: Management of Oligometastatic Disease
Ryan Moy, MD, PhD (Columbia University Cancer Center)
9:20 AM
Endoscopic Management of Upper Gastrointestinal Cancers
Seung Eun (Grace) Lee, MD (Memorial Sloan Kettering Cancer Center)
9:30 AM
Panel Discussion and Q&A
Networking Break
10:00 AM - 10:30 AM
ACL Live, Music Porch and PNC Hall
Upper GI Cancers: Late Stage
Session Chair: Samuel Klempner, MD (Mass General Brigham Cancer Institute)
ACL Live, General Session
10:30 AM
Selecting the Optimal First-Line Target: HER2, PD-L1, CLDN18.2, and FGFR2
Darshil Shah, MD, MPH (Ironwood Cancer & Research Center)
10:40 AM
Biomarkers & Patient Selection for Immunotherapy
Nataliya Uboha, MD, PhD (University of Wisconsin Health)
10:50 AM
Second Line Treatment Options
Rutika Mehta, MD, MPH (NYU Langone Health)
11:00 AM
Applying NGS to Clinical Management of Upper GI Cancers
Steven Maron, MD, MSc (Memorial Sloan Kettering Cancer Center)
11:10 AM
Panel Discussion and Q&A
Lunch Industry Symposium (Non-CE)
11:55 AM - 12:55 PM
W Austin Hotel, Great Room
RASONQUE: Breaking Barriers in Metastatic Pancreatic Adenocarcinoma by Targeting RAS
Shiraj Sen, MD, PhD (Texas Oncology)
Sponsored by: Revolution Medicines
Industry attendance is limited to lunch symposium sponsors only
Colorectal Cancer, Part I: Early Stage
Session Chair: Cathy Eng, MD, FACP, FASCO (Vanderbilt University Medical Center)
ACL Live, General Session
1:10 PM
Surgical Approaches
Seth Felder, MD (Moffitt Cancer Center)
1:20 PM
Radiation Approaches
Karyn Goodman, MD (Icahn School of Medicine at Mount Sinai)
1:30 PM
IO & Emerging Treatments
Richard Kim, MD (Moffitt Cancer Center)
1:40 PM
Panel Discussion and Q&A
Colorectal Cancer, Part II: Late Stage
Session Chair: Tiago Biachi de Castria, MD, PhD (Moffitt Cancer Center)
ACL Live, General Session
2:05 PM
Targeted Therapies: BRAF, HER2, KRAS
Eric Lander, MD (Minnesota Oncology)
2:15 PM
New Approaches to Chemotherapy
Michael Overman, MD (MD Anderson Cancer Center)
2:25 PM
Liver-Directed Therapies for Unresectable Colorectal Liver Metastases
Michael Lidsky, MD, FACS (Duke Cancer Center)
2:35 PM
Panel Discussion and Q&A
Networking Break
3:00 PM - 3:30 PM
ACL Live, Music Porch and PNC Hall
Liver & Biliary Cancers
Session Chair: Mark Yarchoan, MD (Johns Hopkins Kimmel Cancer Center)
ACL Live, General Session
3:30 PM
HCC
Benjamin Kitchens, MD (Texas Oncology)
3:40 PM
BTC
Haley Ellis, MD (Mass General Brigham Cancer Institute)
3:50 PM
Multidisciplinary Approach
Shaun McKenzie, MD, FACS (Texas Oncology)
4:00 PM
Panel Discussion and Q&A
James Harding, MD (Memorial Sloan Kettering Cancer Center)
